Conference Coverage

Model could reduce some disparities in lung cancer screening


 

FROM WCLC 2020

More and widening disparity

The results showed that augmenting USPSTF criteria to include high-benefit people selected significantly more African Americans than Whites and could therefore reduce or even eliminate disparities between Whites and African Americans.

“The 2020 USPSTF draft recommendations would make 6.5 million more people eligible to be screened, in addition to the 8 million from the 2013 criteria,” said Gerard Silvestri, MD, of the Medical University of South Carolina, Charleston, who was not involved in this study.

“But there will be more White people than African American people added, and the disparity between them may widen. Using the risk prediction model outlined in this well-researched study could close the gap in disparity. It’s important to identify individual risk and life expectancy.”

Dr. Silvestri pointed out that, compared to Whites, African Americans develop lung cancer at an earlier age with fewer pack-years history of smoking and have worse outcomes.

“We can’t just focus on one aspect of disparity,” he said. “African Americans are much less likely to be insured or to identify a primary care provider for integrated care. We know that screening works. The 2020 USPSTF draft recommendations will enlarge the pool of eligible African Americans and reduce disparities if the other part of the equation holds; that is, they get access to care and screening.”

This study was funded by the National Institutes of Health/National Cancer Institute. Dr. Landy and Dr. Silvestri have no disclosures.

Pages

Recommended Reading

Model predicts acute kidney injury in cancer patients a month in advance
AVAHO
COVID-19 vaccination in cancer patients: NCCN outlines priorities
AVAHO
Pandemic seems to impact lung cancer diagnosis and prognosis
AVAHO
Screening for lung cancer in never-smokers is ‘feasible’
AVAHO
Nivolumab improves survival in relapsed mesothelioma
AVAHO
‘Astonishing’ 4-year survival in NSCLC with pembro plus chemo
AVAHO
Death rates ‘remain high’ in patients with thoracic cancers and COVID-19
AVAHO
Managing cancer outpatients during the pandemic: Tips from MSKCC
AVAHO
Neoadjuvant atezolizumab safe for patients with resectable lung cancer
AVAHO
Customized chemotherapy did not improve survival in early NSCLC
AVAHO